Clinical Trial Update: Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer [NA]

View source ↗

Summary

Clinical trial update for M5A, a Copper-64 labeled anti-CEA monoclonal antibody used in PET imaging to diagnose CEA-positive cancers; the study is active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Extrahepatic Cholangiocarcinoma
• Gallbladder Cancer
• Intrahepatic Cholangiocarcinoma
• Liver Cancer
• Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• M5A (Copper-64 labeled anti-CEA monoclonal antibody)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Breast Cancer, Colon Cancer | NA | Status: ACTIVE_NOT_RECRUITING | Results posted: 2023-04-21